Pimavanserin
Active ingredient: Pimavanserin Tartrate
In short: Pimavanserin capsule is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis .
What is Pimavanserin used for?
Pimavanserin capsule is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis .
⚠ Boxed warning (FDA's strongest warning)
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Pimavanserin is not approved for the treatment of patients with dementia who experience psychosis unless their hallucinations and delusions are related to Parkinson’s disease
.
Pimavanserin dosage
The recommended dose of pimavanserin capsule is 34 mg taken orally once daily, without titration.
Pimavanserin capsule can be taken with or without food
.
Pimavanserin capsules can be taken whole, or opened and the entire contents sprinkled over a tablespoon (15 mL) of applesauce, yogurt, pudding, or a liquid nutritional supplement. Consume the drug/food mixture immediately without chewing; do not store for future use.
Coadministration with Strong CYP3A4 Inhibitors
The recommended dose of pimavanserin capsules when coadministered with strong CYP3A4 inhibitors is 10 mg, taken orally as one tablet once daily .
Coadministration with Strong or Moderate CYP3A4 Inducers
Avoid concomitant use of strong or moderate CYP3A4 inducers with pimavanserin capsules .
How to take Pimavanserin — instructions & advice from the label
Concomitant Medication
Advise patients to inform their healthcare providers if there are any changes to their current prescription or over-the-counter medications, since there is a potential for drug interactions .
Administration Instructions
Advise patients to take the capsule whole or sprinkled over a tablespoon (15 mL) of applesauce, yogurt, pudding, or a liquid nutritional supplement. Advise patients to consume the drug/food mixture immediately and not to store for future use .
Manufactured by:
MSN Pharmaceuticals Inc
Piscataway, NJ 08854
Distributed by:
Novadoz Pharmaceuticals LLC
Piscataway, NJ 08854-3714
Issued on: October 2023
Warnings & precautions
Do not take this medicine if: Pimavanserin is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported .
Antipsychotic drugs increase the all-cause risk of death in elderly patients with dementia-related psychosis. Analyses of 17 dementia-related psychosis placebo-controlled trials (modal duration of 10 weeks and largely in patients taking atypical antipsychotic drugs) revealed a risk of death in the drug-treated patients of between 1.6- to 1.7-times that in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in placebo-treated patients. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Pimavanserin is not approved for the treatment of patients with dementia who experience psychosis unless their hallucinations and delusions are related to Parkinson’s disease .
Pimavanserin prolongs the QT interval. The use of pimavanserin should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin, moxifloxacin) . …
Pimavanserin side effects
The following serious adverse reactions are discussed elsewhere in the labeling:
Increased Mortality in Elderly Patients with Dementia-Related Psychosis
QT Interval Prolongation
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The clinical trial database for pimavanserin consists of over 1200 subjects and patients exposed to one or more doses of pimavanserin. Of these, 616 were patients with hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). In the placebo-controlled setting, the majority of experience in patients comes from studies evaluating once-daily pimavanserin doses of 34 mg (N=202) compared to placebo (N=231) for up to 6 weeks. In the controlled trial setting, the study population was approximately 64% male and 91% Caucasian, and the mean age was about 71 years at study entry. Additional clinical trial experience in patients with hallucinations and delusions associated with PDP comes from two open-label, safety extension studies (total N=497). The majority of patients receiving long-term treatment received 34 mg once-daily (N=459). Over 300 patients have been treated for more than 6 months; over 270 have been treated for at least 12 months; and over 150 have been treated for at least 24 months. …
Drug interactions
Table 2 Clinically Important Drug Interactions with Pimavanserin
QT Interval Prolongation
Clinical Impact: | Concomitant use of drugs that prolong the QT interval may add to the QT effects of pimavanserin and increase the risk of cardiac arrhythmia.
Intervention: | Avoid the use of pimavanserin in combination with other drugs known to prolong QT interval (e.g., Class 1A antiarrythmics, Class 3 antiarrythmics, certain antipsychotics or antibiotics)
.
Strong CYP3A4 Inhibitors
Clinical Impact: | Concomitant use of pimavanserin with a strong CYP3A4 inhibitor increases pimavanserin exposure
.
Intervention: | If pimavanserin is used with a strong CYP3A4 inhibitor, reduce the dosage of pimavanserin .
Strong or Moderate CYP3A4 Inducers
Clinical Impact: | Concomitant use of pimavanserin with strong or moderate CYP3A4 inducers reduces pimavanserin exposure .
Intervention: | Avoid concomitant use of strong or moderate CYP3A4 inducers with pimavanserin .
Based on pharmacokinetic studies, no dosage adjustment of carbidopa/levodopa is required when administered concomitantly with pimavanserin .
About this medicine
Pimavanserin capsule contains pimavanserin, an atypical antipsychotic, which is present as pimavanserin tartrate salt with the chemical name, urea, N-[(4-fluorophenyl)methyl]-N-(1-methyl-4-piperidinyl)-N’-[[4-(2-methylpropoxy)phenyl]methyl]-,(2R,3R)-2,3-dihydroxybutanedioate (2:1). Pimavanserin tartrate is freely soluble in water, soluble in dichloromethane and practically insoluble in cyclohexane. Its molecular formula is (C25H34FN3O2)2.C4H6O6 and its molecular weight is 1005.20 (tartrate salt). The chemical structure is:
The molecular formula of pimavanserin free base is C25H34FN3O2 and its molecular weight is 427.55. Pimavanserin capsules are intended for oral administration only. Each capsule contains 40 mg of pimavanserin tartrate, which is equivalent to 34 mg of pimavanserin free base. Inactive ingredients include polyethylene glycol. Additionally, the following inactive ingredients are present as components of the capsule shell: FD&C blue #1, hypromellose, titanium dioxide, and yellow iron oxide. The printing ink contains shellac, propylene glycol, black iron oxide. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 403b6540-c53d-4e92-91b4-36ca6338b2b1. Read the full official label on DailyMed.